Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Keegan Nicodemus

Emergency Medicine Birmingham, AL Medical Doctor

NPI 1972063824 CMS profile 8957511

625 19Th St S, Birmingham, AL 35233

Open in the dashboard

General payments

$934

9 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Keegan Nicodemus of Birmingham, AL is reported in the CMS Open Payments database as having received $934 across 9 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $202 2
2024 General $290 2
2023 General $300 3
2022 General $17 1
2021 General $124 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Keegan Nicodemus
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Keegan Nicodemus were reported at $202. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Keegan Nicodemus Emergency Medicine median Middle half National median
2019 $0 $51 $18–$128 $163
2020 $0 $29 $16–$99 $114
2021 $124 $40 $18–$124 $132
2022 $17 $49 $20–$134 $149
2023 $300 $51 $22–$142 $160
2024 $290 $52 $22–$150 $164
2025 $202 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Stryker Corporation $202 2 payments
  2. Abiomed $155 1 payment
  3. Inari Medical, Inc. $151 1 payment
  4. Silk Road Medical, Inc. $139 1 payment
  5. AbbVie, Inc. $125 1 payment
  6. E.R. Squibb & Sons, L.L.C. $124 1 payment
  7. Janssen Pharmaceuticals, Inc $38 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $934 9 payments
Products named General payments · program years 2021–2025
  1. ARTIX MT $202 2 payments
  2. Impella $155 1 payment
  3. FLOWTRIEVER CATHETER, S $151 1 payment
  4. CT THROMBECTOMY SYSTEM KIT $151 1 payment
  5. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $139 1 payment
  6. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $139 1 payment
  7. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $139 1 payment
  8. ENROUTE Transcarotid Stent $139 1 payment
  9. DALVANCE $125 1 payment
  10. ELIQUIS $124 1 payment
  11. Other $38 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

184

Median for Emergency Medicine: 88

Drug cost

$2,350

Median for Emergency Medicine: $590

Branded share of claims

32.1%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cefpodoxime Proxetil Generic 21 $1,528
Methylprednisolone Generic 37 $274
Ondansetron Odt Ondansetron Brand 46 $231
Doxycycline Hyclate Generic 11 $80
Cephalexin Generic 12 $60
Oxycodone Hcl Generic 20 $59
Cyclobenzaprine Hcl Generic 13 $43
Methocarbamol Generic 11 $39
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 13 $36

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$35,846

Medicare's payments for the services billed

Medicare patients

289

Average age 73

Services billed

444

169 women, 120 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Ischemic heart disease 45%
Chronic kidney disease 41%
Diabetes 39%
Depression 38%
Atrial fibrillation 33%
Heart failure 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

9 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record